# PRODUCT INFORMATION



**BLU-285** 

Item No. 22985

CAS Registry No.: 1703793-34-3

Formal Name:  $(\alpha S)$ -(4-fluorophenyl)- $\alpha$ -methyl-2-[4-[6-

> (1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f] [1,2,4]triazin-4-yl]-1-piperazinyl]-5-


pyrimidinemethanamine

Synonym: **Avapritinib** MF: C26H27FN10 FW: 498.6 **Purity:** ≥98%

 $\lambda_{\text{max}}$ : 254, 309 nm UV/Vis.: A crystalline solid Supplied as:

-20°C Storage: Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



### **Laboratory Procedures**

BLU-285 is supplied as a crystalline solid. A stock solution may be made by dissolving the BLU-285 in the solvent of choice, which should be purged with an inert gas. BLU-285 is soluble in organic solvents such as ethanol and DMSO. The solubility of BLU-285 in these solvents is approximately 3 and 66 mg/ml, respectively.

### Description

BLU-285 is a dual inhibitor of KIT receptor and platelet-derived growth factor receptor α (PDGFRα) tyrosine kinases with activating loop mutations (IC<sub>50</sub>s = 0.27 and 0.24 nM for KIT<sup>D816V</sup> and PDGFR $\alpha$ <sup>D842V</sup>, respectively). <sup>1</sup> It is >150-fold selective for KIT<sup>D816V</sup> and PDGFR $\alpha$ <sup>D842V</sup> over a kinase panel at a concentration of 3 μM. BLU-285 also has activity against a panel of KIT and PDGFRα loop mutants identified in patients with gastrointestinal stromal tumors (GISTs;  $IC_{50}$ S = <100 nM). It inhibits growth of cancer cell lines containing wild-type and mutant KIT and PDGFR $\alpha$ , demonstrating increased potency in cell lines expressing KIT and PDGFRα with activating loop mutations. BLU-285 (0.3-30 mg/kg) reduces tumor volume in a P815 KIT<sup>D814Y</sup> mastocytoma allograft mouse model and a GIST patient-derived mouse xenograft model in a dosedependent manner. Formulations containing BLU-285 have been used to treat KIT- and PDGFRq-driven malignancies.

### Reference

1. Evans, E.K., Gardino, A.K., Kim, J.L., et al. A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci. Transl. Med. 9(414), eaao1690 (2017).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

## WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the mater can be found on our website.

Copyright Cayman Chemical Company, 12/06/2022

### **CAYMAN CHEMICAL**

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM